A randomized, double-blind, comparative study of terbinafine <i>vs</i> griseofulvin in tinea capitis

Haroon, Tahir Saeed; Hussain, Irshad; Aman, Shahbaz; Nagi, A. H.; Ahmad, Imtiaz; Zahid, Maria; Alvi, K. H.; Iqba1, N; Khan, Kanwal Iqbal

doi:10.3109/09546639209088698

Cited by 24 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Randomized comparison studies of griseofulvin versus ketaconazole have shown ketaconazole to be less effective in treating tinea capitis (15, 16). Terbinafine has been reported to be as effective as griseofulvin, and a shorter duration of treatment is required with terbinafine (17, 18). To the best of our knowledge, itraconazole and fluconazole have not been directly compared with griseo‐fulvin.…”

Section: Discussionmentioning

confidence: 99%

Clinico‐Mycological Profile of Tinea Capitis in North India and Response to Griseofulvin

Singal

Rawat

Bhattacharya

et al. 2001

The Journal of Dermatology

View full text Add to dashboard Cite

There is a paucity of literature on tinea capitis from North India. The response to griseofulvin has not been studied as well. We studied 153 consecutive patients of tinea capitis for clinical patterns, causative dermatophytic species, clinico-etiological correlation, and response to griseofulvin. Culture and sensitivity were done on all patients. All patients were treated with griseofulvin for 6-8 weeks; non-responders were further treated with fluconazole. Ninety percent of the patients were less than 15 years of age, 75% belonged to poor socioeconomic groups and 19% had a family history of tinea capitis. The seborrheic variant was the commonest clinical pattern seen in 47.8% of patients, followed by grey patch, black dot, kerion, and alopecia-areata-like tinea capitis in 35.9%, 8.5%, 6.5% and 1.3% of patients, respectively. Only 66% of patients had a positive culture. T. violaceum was the commonest dermatophytic species isolated in 38% patients. M. audouinii, T. schoenleinii, T. tonsurans, M. gypseum, T. verrucosum and T. mentagrophytes were isolated in 34%, 10%, 9%, 3%, 3% and 3% of patients, respectively. Of the isolates 94% were susceptible to griseofulvin, and 100% were susceptible to fluconazole. By using griseofulvin for 6-8 weeks 97.4% of the patients were cured; nonresponders required therapy with fluconazole for cure. To conclude, tinea capitis is still a disease of younger people of poor socioeconomic status. T. violaceum and M. audouinii are the most common responsible dermatophytes. The response to griseofulvin was excellent, and it should be used as a first line therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinico‐Mycological Profile of Tinea Capitis in North India and Response to Griseofulvin

Singal

Rawat

Bhattacharya

et al. 2001

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6][7][8][9] As no case attributable to Microsporum species was treated, it is not possible to deduce how this infection would respond to 2 weeks of therapy with either drug. The results of our study suggest that both these drugs fulfil the above criteria equally well.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4][5][6][7][8][9] Based on their peculiar pharmacokinetic properties and previous data, it can be presumed that both these drugs will be effective when given as continuous therapy for 2 weeks. [1][2][3][4][5][6][7][8][9] Based on their peculiar pharmacokinetic properties and previous data, it can be presumed that both these drugs will be effective when given as continuous therapy for 2 weeks.…”

mentioning

confidence: 99%

A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis

Jahangir

Hussain

Hasan

et al. 1998

British Journal of Dermatology

View full text Add to dashboard Cite

In this randomized, double-blind study, the efficacy and safety of oral itraconazole (n = 28) and terbinafine (n = 27), each given for 2 weeks, was compared in patients with tinea capitis. Trichophyton violaceum was the major pathogen in both groups (82.1% and 88.9%, respectively). The final evaluation at week 12 showed a cure rate of 85.7% and 77.8%, respectively (P > 0.05). Adverse events noted were mild and did not warrant discontinuation of therapy.

show abstract

“…However, all 9 non-responders had this dermatophyte, suggesti ng that the durati on of therapy has to be extended beyond 2 weeks in certain cases of T. rubrum infecti on. Although the number of cases resulti ng from other pathogens was small, they do respond to this short-term therapy with drug usually in Tenia capiti s. [6][7][8][9][10][11][12][13] Bothitraconazole and terbinafi ne are highly lipophilic and kerati nophilic. They persist in the stratum corneum and hair in high concentrati ons for 3-4 weeks aft er therapy is disconti nued.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Itraconazole Versus Terbinafine for the Treatment of Tineacruris.

Shakya

Jha

Dangol

et al. 2013

Med. J. Shree Birendra Hosp.

View full text Add to dashboard Cite

Introducti on: Tenia Cruris is the commonest dermatophyte infecti on which is common in men and aggravated by warm humid conditi on Teniarubrum is the main species for the disease 1,2 . Itraconazole and Terbinafi ne are the bett er newer drugs for the therapeuti c opti on due to their effi cacy, convenient and less side eff ect. Itraconazole is a wider spectrum Thiazole group of fungistati c drugs which inhibit sterol 14 α demethylase impairing biosynthesis of fungal ergosterol. Similarly Terbinafi ne is broad specturmallylamine group of fungicidal acti vity which inhibits squalene 2, 3 epoxidase enzyme thus inhibit fungal biosynsthesis of ergosterol [3][4][5] . These two drugs have been needed conventi onally as a pulse and conti nuous therapy. The main aim of this study is to compare the effi cacy of both drugs and to recommend the eff ecti ve treatment in case of Teniacruris. Methods:In this randomized comparati ve study, the effi cacy and safety of oral itraconazole (n=35) and terbinafi ne (n=35), each given for 2weeks, was compared in pati ents with ti neacruris within the period of 1 year study. Results:The fi nal evaluati on at week 4 showed a cure rate of 91.4% for itraconazole and 82.9% for terbinafi ne. No defi nite adverse eff ect was noted. Conclusions:Itraconazolehas high cure rate and less failure rate without side eff ects in comparision toTerbinafi ne.

show abstract

A randomized, double-blind, comparative study of terbinafine vs griseofulvin in tinea capitis

Cited by 24 publications

References 5 publications

Clinico‐Mycological Profile of Tinea Capitis in North India and Response to Griseofulvin

Clinico‐Mycological Profile of Tinea Capitis in North India and Response to Griseofulvin

A double-blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis

Efficacy of Itraconazole Versus Terbinafine for the Treatment of Tineacruris.

Contact Info

Product

Resources

About